{Reference Type}: Case Reports
{Title}: Successful treatment for serious depression with suicidal risk in a heart transplant patient.
{Author}: Arango-Posada MDM;Prada-Escobar AI;Marín-Hernández C;Monsalve-Franco V;Restrepo-Bernal D;
{Journal}: Rev Colomb Psiquiatr (Engl Ed)
{Volume}: 53
{Issue}: 2
{Year}: 2024 Apr-Jun 9
暂无{DOI}: 10.1016/j.rcpeng.2022.03.001
{Abstract}: <B>BACKGROUND: </B>Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes.<BR><B>METHODS: </B>We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 h, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 h after the infusion.<BR><B>CONCLUSIONS: </B>Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis.<BR><B>CONCLUSIONS: </B>Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.